
Ryota Kikuchi, PhD, AbbVie Inc.
personal info
Dr. Kikuchi received PhD in Pharmaceutical Sciences from the University of Tokyo in 2007 under the supervision by Prof. Sugiyama. After spending 1 year as a postdoc in the same laboratory and another 1 year and half in Roche (Palo Alto, CA), he joined Abbott/AbbVie as a senior scientist in 2009. Currently, he leads the Translational PK and DDI Sciences group within Quantitative, Translational & ADME Sciences (QTAS) organization at AbbVie. The group is responsible for human PK and DDI predictions of small molecule drug candidates from early (e.g. LO) to late stage (e.g. IND) in drug discovery by integrating various approaches (e.g. PBPK, IVIVE, allometric scaling, static- and dynamic-DDI predictions) and providing fit-for-purpose support to project teams. Dr. Kikuchi also supports clinical development projects by providing input to the design, conduct and interpretation of clinical DDI studies as well as preparing responses to DDI-related questions from regulatory agencies (e.g. FDA, EMA, PMDA). Dr. Kikuchi has a strong background and almost 25 years of experiences in drug transporter, enzymology, DDI and in vivo pharmacokinetics. He was a co-chair of the IQ OATP1B biomarker working group from 2021 to 2023. Besides being a SME of human PK and DDI predictions and drug transporters, he has >10 years of experiences as a DMPK-representative supporting both discovery and development projects.